1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with ALS - Amyotrophic Lateral Sclerosis in 4 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Moreover, fasudil slowed disease progression, increased survival time and reduced motor neuron loss, in SOD1(G93A) mice." | 5.39 | Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. ( Hara, H; Kawasaki, K; Kimura, M; Nagahara, Y; Seto, M; Shimazawa, M; Takata, M; Tanaka, H; Tanaka, K; Tsuruma, K, 2013) |
| "Moreover, fasudil slowed disease progression, increased survival time and reduced motor neuron loss, in SOD1(G93A) mice." | 1.39 | Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. ( Hara, H; Kawasaki, K; Kimura, M; Nagahara, Y; Seto, M; Shimazawa, M; Takata, M; Tanaka, H; Tanaka, K; Tsuruma, K, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martín-Cámara, O | 1 |
| Arribas, M | 1 |
| Wells, G | 1 |
| Morales-Tenorio, M | 1 |
| Martín-Requero, Á | 1 |
| Porras, G | 1 |
| Martínez, A | 1 |
| Giorgi, G | 1 |
| López-Alvarado, P | 1 |
| Lastres-Becker, I | 1 |
| Menéndez, JC | 1 |
| Takata, M | 1 |
| Tanaka, H | 1 |
| Kimura, M | 1 |
| Nagahara, Y | 1 |
| Tanaka, K | 1 |
| Kawasaki, K | 1 |
| Seto, M | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Hara, H | 1 |
| Tönges, L | 1 |
| Günther, R | 1 |
| Suhr, M | 1 |
| Jansen, J | 1 |
| Balck, A | 1 |
| Saal, KA | 1 |
| Barski, E | 1 |
| Nientied, T | 1 |
| Götz, AA | 1 |
| Koch, JC | 1 |
| Mueller, BK | 1 |
| Weishaupt, JH | 1 |
| Sereda, MW | 1 |
| Hanisch, UK | 1 |
| Bähr, M | 1 |
| Lingor, P | 1 |
| Krieger, C | 1 |
| Wagey, R | 1 |
| Lanius, RA | 1 |
| Shaw, CA | 1 |
4 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and ALS - Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral Sclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Amyotrophic Lateral Sclerosis; Cell Line, Tumor | 2022 |
Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amyotrophic Lateral Sclerosis; Animals; Disease Model | 2013 |
Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amyotrophic Lateral Sclerosis; Animals; Astrocytes; A | 2014 |
Activation of PKC reverses apparent NMDA receptor reduction in ALS.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Amyotrophic Lateral Sclerosis; Autoradiography; | 1993 |